Novartis Ag

Novartis Pharma Gmbh

Holger Sellner

Juergen Klaus Maibaum

Claus Ehrhardt

Richard Sedrani

Nils Ostermann

Daniel Baeschlin

Werner Breitenstein

Pascal Furet

Sylvain Cottens

Oliver Simic

Joerg Kallen

Wolfgang Miltz

Edwige Liliane Jeanne Lorthiois

Stefan Andreas Randl

Markus Wartmann

Osamu Irie

Michael A Dechantsreiter

Nicolas Soldermann

Bahaa Salem

Vincent Bordas

Jonathan E Grob

Finton Sirockin

Tobias Schmelzle

Patricia Imbach-weese

Aengus Macsweeney

Mickael Le Douget

Joseph McKENNA

Markus Voegtle

Vito Guagnano

Cara Brocklehurst

Edwige Liliane Lorthiois

Eric Valeur

Daniel Kaspar Baeschlin

Edgar Jacoby

Aengus Mac Sweeney

Jürgen Klaus Maibaum

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;

Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors

The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 

Complement pathway modulators and uses thereof

Compounds of the present invention having the formula exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

4-phenylpiperidine derivatives as renin inhibitors

Disclosed are &#x3b4;-amino-&#x3b3;-hydroxy-&#x3c9;-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

&#x3b4;-amino-&#x3b3;-hydroxy-&#x3c9;-aryl-alkanoic acid amides

&#x3b4;-amino-&#x3b3;-hydroxy-&#x3c9;-aryl-alkanoic acid amide compound

The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis.

Organic compounds

Compounds of the present invention having the formula (I) exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders. 

Growing community of inventors

Therwil, Switzerland

Holger Sellner